Oppenheimer Reiterates Outperform Rating on Veru (VERU) Ahead of sabizabulin EMA Decision
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $36.00 price target on Veru, Inc. (NASDAQ: VERU), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
